BioLineRx (NASDAQ:BLRX) Issues Earnings Results

BioLineRx (NASDAQ:BLRX) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.62), Zacks reports. BioLineRx had a negative return on equity of 37.73% and a negative net margin of 563.70%.The business had revenue of $0.29 million for the quarter, compared to analysts’ expectations of $0.50 million.

BioLineRx Stock Performance

BioLineRx stock opened at $2.60 on Monday. The stock has a fifty day moving average price of $2.92 and a 200 day moving average price of $2.84. BioLineRx has a 52 week low of $2.15 and a 52 week high of $4.56. The firm has a market capitalization of $11.36 million, a P/E ratio of -1.35 and a beta of 1.54. The company has a current ratio of 1.58, a quick ratio of 1.43 and a debt-to-equity ratio of 0.16.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of BioLineRx in a research report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, BioLineRx has a consensus rating of “Sell”.

BioLineRx Company Profile

BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.

Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.